CN Mobile Logo


Thyroid Cancer

ASCO 2016 Genitourinary Cancers Symposium

Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium, held January 7–9 in San Francisco. We’ll bring you reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way genitourinary cancers are managed and treated.

Thyroid Cancer

An increased rate of adverse effects is seen in patients with differentiated thyroid cancer who are being treated with the tyrosine kinase inhibitor sorafenib.

The use of a standard yearly physical examination to screen for thyroid cancer among high-risk survivors of childhood and young adult cancers resulted in a negative predictive value of 100% for clinically relevant thyroid cancer and a significant cost savings compared with regular ultrasound screening.

Survivors of thyroid cancer are at an increased risk for developing a second cancer, according to the results of a recently published study.

Regular ultrasound surveillance of the thyroid revealed that about 7% of adult childhood cancer survivors who had radiation to the head or neck subsequently developed thyroid cancer.

Researchers identified a novel gene that may predispose individuals to Cowden syndrome, an inherited condition that carries an especially high risk for various epithelial cancers and especially thyroid cancer.

The overall risk of developing a second primary thyroid or breast tumor is higher in patients with prior breast or thyroid cancer.

The coexistence of mutations in telomerase reverse transcriptase (TERT) and BRAF genes dramatically increases the risk of thyroid cancer aggressiveness, tumor recurrence and thyroid cancer-specific deaths.


Subscribe to Thyroid Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.